Lixisenatide

ArtNr	HY-P0119-100mg
Hersteller	MedChem Express
CAS-Nr.	320367-13-3
Menge	100 mg
Quantity options	100 mg 10 mMx1 mL 10 mg 1 mg 25 mg 2 mg 50 mg 5 mg
Kategorie	Metabolism Diabetes Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.93
Citations	[1]Ahrén B et al. Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. Diabetes Ther. 2016 Jun 18\|[2]Lorenz M, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia. Regul Pept. 2013 Aug 10;185:1-8.\|[3]D Tews, et al. Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues. Horm Metab Res. 2008 Mar;40(3):172-80.\|[4]Ulrich Werner, et al. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept. 2010 Sep 24;164(2-3):58-64.\|[5]Mikkel Christensen, et al. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs. 2009 Aug;12(8):503-13.\|[6]Cai H Y, et al. Lixisenatide attenuates the detrimental effects of amyloid β protein on spatial working memory and hippocampal neurons in rats [J]. Behavioural brain research, 2017, 318: 28-35.\|[7]Vinué Á, et al. The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype [J]. Diabetologia, 2017, 60: 1801-1812.\|[8]Du X, et al. The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes [J]. International immunopharmacology, 2019, 75: 105732.\|[9]Abdel-Latif R G, et al. Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats [J]. Life Sciences, 2020, 263: 118592.\|[10]Xiao M, et al. The protective effects of GLP-1 receptor agonist lixisenatide on oxygen-glucose deprivation/reperfusion (OGD/R)-induced deregulation of endothelial tube formation [J]. RSC advances, 2020, 10(17): 10245-10253.
Smiles	O=C(NCC(N[C@@H](CCC(O)=O)C(NCC(N[C@@H]([C@H](O)C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCSC)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC3=CNC4=CC=CC=C34)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CC(N)=O)C(NCC(NCC(N5[C@@H](CCC5)C(N[C@@H](CO)C(N[C@@H](CO)C(NCC(N[C@@H](C)C(N6[C@@H](CCC6)C(N7[C@@H](CCC7)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC8=CNC=N8)N
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Versandbedingung	Gekühlt
Lieferbar
Manufacturer - Type	Peptides
Manufacturer - Applications	Metabolism-sugar/lipid metabolism
Manufacturer - Targets	Akt; GCGR; JNK; MEK; MMP
Shipping Temperature	Blue Ice
Storage Conditions	-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Molecular Weight	4858.49
Product Description	Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe−/− Irs2+/− mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation[2][3][5].
Manufacturer - Research Area	Metabolic Disease; Inflammation/Immunology; Neurological Disease
Solubility	H2O: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	GPCR/G Protein; MAPK/ERK Pathway; Metabolic Enzyme/Protease; PI3K/Akt/mTOR
Isoform	MEK1; MEK2; MMP-1; MMP-13; MMP-3
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-P0119-100mg-safety-datasheet.pdf